Transforming drug discovery through polymathic AI
Our mission is to develop cutting-edge therapeutics that improve the lives of patients
CoSyne is a visionary drug discovery company applying polymathic AI to transform the way medicines are discovered.
Focusing on moonshot projects, our compound discovery engine is combined with our target discovery engine to create a step change in the way drugs are developed: hypothesis-free drug discovery that can address devastating diseases from the ground up.
We have built a proprietary pipeline targeting rare, fatal orphan diseases.
Dr. Louwai Muhammed
CEO & Co-founder
Neurologist with a background in biomedical entrepreneurship. Studied neuroscience at Cambridge and clinical medicine at Oxford. Graduated top of his year and was the first medical student in Oxford history to be awarded merits in every exam. Top ranking applicant to London academic medical training and was the highest scoring applicant to neurology specialist training in the UK. Awarded a Kennedy Scholarship to Harvard where he studied entrepreneurship, negotiation, and communication. Winner of the MIT-$100K Accelerate competition. Established an internationally recognised teaching platform for medical students in war-zones.
Dr. Liisi Laaniste
CSO & Co-founder
PhD from Imperial College London in Computational Systems Biology. Over 7-years of research on brain tumours, glioma microenvironments and vasculature, cancer genetics and pathways of malignant transformation. Studied neuroscience in Karolinska Institute, medical science in Uppsala University and was ranked first in genetics at University of Tartu, graduating cum laude. Awarded multiple scholarships including the highly competitive Imperial College President’s scholarship.
Prof. Michael Johnson
CMO & Co-founder
Professor of Neurology and Genomic Medicine at Imperial College London with over 15-year’s experience with pharmaceutical and biotechnology companies. Graduated from Oxford (PhD in molecular genetics) and St Bartholomew’s Hospital Medical School (Medicine). Over 20-years’ experience as Principle Investigator at Imperial College in genetics and genomics and as a consultant clinical neurologist at Imperial College Healthcare. Professor Johnson pioneered the development of applied systems biology for drug discovery with over 75 journal articles and book chapters including in Nature, Nature Genetics, Nature Neuroscience, Nature Communications, Genome Research and Nature Reviews Neurology.
Dr. Dean Plumbley
CTO & Head of AI
Experienced computational scientist, bringing state-of-the-art artificial intelligence and mathematical techniques into large scale data applications. Prior experience using machine learning and molecular mechanics for drug design, protein – protein interaction modelling, drug combination therapy design. Former CTO at Bower Game Studio and Omnigen and Senior Machine Learning Scientist at BenevolentAI. PhD in Computer Science from Manchester University.
Dr. Samuel Woodhouse
VP of Operations
R&D and Operations leader with a background in scaling biotechs and building high-performing teams. He has a PhD in Epigenetics and Stem Cell Biology from the University of Cambridge and a 1st class degree in Pharmacology from the University of Edinburgh. He has over a decades’ worth of experience in next-generation sequencing, assay development, and business development, and has launched several commercially successful novel genomic solutions. He has 16 patent families in the fields of cancer biology, single-cell genomics, diagnostics, and cell therapy.
Our team is passionate, visionary and pragmatic. We bring together interdisciplinary skills from across the drug development process, spanning target discovery, AI, chemistry, clinical trials and treating patients in hospital:
Our mission is to develop cutting-edge therapeutics that improve the lives of patients.
We live by our values which determine the way we operate.
For all enquiries, please email us at email@example.com.
We look forward to hearing from you.